OncLive TV

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Benjamin P. Levy, MD, discusses the mechanism ​of action of telaglenastat in non–small cell lung cancer.

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Sarki A. Abdulkadir, MD, PhD, discusses the rationale to target MYC in prostate cancer.

William W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.

Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Michael B. Atkins, MD, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma.